Assessment of secular trends of three major gynecologic cancers burden and attributable risk factors from 1990 to 2019: an age period cohort analysis.
Humans
Female
Risk Factors
Middle Aged
Adult
Aged
Genital Neoplasms, Female
/ epidemiology
Cohort Studies
Disability-Adjusted Life Years
/ trends
Uterine Cervical Neoplasms
/ epidemiology
Uterine Neoplasms
/ epidemiology
Global Health
/ statistics & numerical data
Ovarian Neoplasms
/ mortality
Age Factors
Young Adult
Cost of Illness
Age-period-cohort model
Cervical cancer
Global burden of disease
Ovarian cancer
Uterine cancer
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
19 May 2024
19 May 2024
Historique:
received:
31
10
2023
accepted:
15
05
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
19
5
2024
Statut:
epublish
Résumé
This study aims to assess the long-term trends in the burden of three major gynecologic cancers(GCs) stratified by social-demographic status across the world from 1990 to 2019. To assess the trends of risk factor attributed mortality, and to examine the specific effects of age, period, cohort behind them in different regions. We extracted data on the mortality, disability-adjusted life years(DALYs), and age-standardized rates(ASRs) of cervical cancer(CC), uterine cancer(UC), and ovarian cancer(OC) related to risks from 1990 to 2019, as GCs burden measures. Age-period-cohort analysis was used to analyze trends in attributable mortality rates. The number of deaths and DALYs for CC, UC and OC increased since 1990 worldwide, while the ASDRs decreased. Regionally, the ASDR of CC was the highest in low SDI region at 15.05(11.92, 18.46) per 100,000 in 2019, while the ASDRs of UC and OC were highest in high SDI region at 2.52(2.32,2.64), and 5.67(5.16,6.09). The risk of CC death caused by unsafe sex increased with age and then gradually stabilized, with regional differences. The period effect of CC death attributed to smoking showed a downward trend. The cohort effect of UC death attributed to high BMI decreased in each region, especially in the early period in middle, low-middle and low SDI areas. Global secular trends of attributed mortality for the three GCs and their age, period, and cohort effects may reflect the diagnosis and treatment progress, rapid socioeconomic transitions, concomitant changes in lifestyle and behavioral patterns in different developing regions. Prevention and controllable measures should be carried out according to the epidemic status in different countries, raising awareness of risk factors to reduce future burden.
Sections du résumé
BACKGROUND
BACKGROUND
This study aims to assess the long-term trends in the burden of three major gynecologic cancers(GCs) stratified by social-demographic status across the world from 1990 to 2019. To assess the trends of risk factor attributed mortality, and to examine the specific effects of age, period, cohort behind them in different regions.
METHODS
METHODS
We extracted data on the mortality, disability-adjusted life years(DALYs), and age-standardized rates(ASRs) of cervical cancer(CC), uterine cancer(UC), and ovarian cancer(OC) related to risks from 1990 to 2019, as GCs burden measures. Age-period-cohort analysis was used to analyze trends in attributable mortality rates.
RESULTS
RESULTS
The number of deaths and DALYs for CC, UC and OC increased since 1990 worldwide, while the ASDRs decreased. Regionally, the ASDR of CC was the highest in low SDI region at 15.05(11.92, 18.46) per 100,000 in 2019, while the ASDRs of UC and OC were highest in high SDI region at 2.52(2.32,2.64), and 5.67(5.16,6.09). The risk of CC death caused by unsafe sex increased with age and then gradually stabilized, with regional differences. The period effect of CC death attributed to smoking showed a downward trend. The cohort effect of UC death attributed to high BMI decreased in each region, especially in the early period in middle, low-middle and low SDI areas.
CONCLUSIONS
CONCLUSIONS
Global secular trends of attributed mortality for the three GCs and their age, period, and cohort effects may reflect the diagnosis and treatment progress, rapid socioeconomic transitions, concomitant changes in lifestyle and behavioral patterns in different developing regions. Prevention and controllable measures should be carried out according to the epidemic status in different countries, raising awareness of risk factors to reduce future burden.
Identifiants
pubmed: 38764017
doi: 10.1186/s12889-024-18858-3
pii: 10.1186/s12889-024-18858-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1349Subventions
Organisme : Natural Science Fund for Colleges and Universities in Jiangsu Province
ID : 22KJD310005
Organisme : Outstanding Talent Research Initiation Foundation of Xuzhou Medical University
ID : D2021036
Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708
doi: 10.3322/caac.21708
pubmed: 35020204
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Zhang Y, Luo G, Li M, Guo P, Xiao Y, Ji H, et al. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis. BMC Cancer. 2019;19(1):984. https://doi.org/10.1186/s12885-019-6139-6
doi: 10.1186/s12885-019-6139-6
pubmed: 31640608
pmcid: 6806513
Yang M, Du J, Lu H, Xiang F, Mei H, Xiao H. Global trends and age-specific incidence and mortality of cervical cancer from 1990 to 2019: an international comparative study based on the global burden of disease. BMJ Open. 2022;12(7):e055470. https://doi.org/10.1136/bmjopen-2021-055470
doi: 10.1136/bmjopen-2021-055470
pubmed: 35868828
pmcid: 9316042
Singh M, Jha RP, Shri N, Bhattacharyya K, Patel P, Dhamnetiya D. Secular trends in incidence and mortality of cervical cancer in India and its states, 1990–2019: data from the global burden of disease 2019 study. BMC Cancer. 2022;22(1):149. https://doi.org/10.1186/s12885-022-09232-w
doi: 10.1186/s12885-022-09232-w
pubmed: 35130853
pmcid: 8819855
Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 2020;123(4):510–7. https://doi.org/10.1038/s41416-020-0920-9
doi: 10.1038/s41416-020-0920-9
pubmed: 32507855
pmcid: 7434873
Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynecol. 2017;41:3–14. https://doi.org/10.1016/j.bpobgyn.2016.08.006
doi: 10.1016/j.bpobgyn.2016.08.006
Randall TC, Goodman A, Schmeler K, Durfee J, Pareja R, Munkarah A, et al. Cancer and the world’s poor: what’s a gynecologic cancer specialist to do? Gynecol Oncol. 2016;142(1):6–8. https://doi.org/10.1016/j.ygyno.2016.05.018
doi: 10.1016/j.ygyno.2016.05.018
pubmed: 27210817
Foster AA, Murphy GT, Neufeld V. Facing a paradigm shift in the sustainable development goal era. World Health Popul. 2017;17(3):4–10. https://doi.org/10.12927/whp.2017.25310
doi: 10.12927/whp.2017.25310
pubmed: 29400269
Zhou Z, Wang X, Ren X, Zhou L, Wang N, Kang H. Disease burden and attributable risk factors of ovarian cancer from 1990 to 2017: findings from the global burden of disease study 2017. Front Public Health. 2021;9:619581. https://doi.org/10.3389/fpubh.2021.619581
doi: 10.3389/fpubh.2021.619581
pubmed: 34604147
pmcid: 8484795
Huang J, Chan WC, Ngai CH, Lok V, Zhang L, Lucero-Prisno DE, et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers (Basel). 2022;14(9). https://doi.org/10.3390/cancers14092230 . 3rd.
Zhao Y, Qiu P, Yan L, Li S, Yang Z, Zhang H, et al. Epidemiological trends of female breast and gynecologic cancers in adolescents and young adults in China from 1990 to 2019: results from the global burden of disease study 2019. Front Oncol. 2022;12:1003710. https://doi.org/10.3389/fonc.2022.1003710
doi: 10.3389/fonc.2022.1003710
pubmed: 36313685
pmcid: 9606349
GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the global burden of disease study 2019. Lancet. 2022;400(10352):563–91. https://doi.org/10.1016/s0140-6736(22)01438-6
doi: 10.1016/s0140-6736(22)01438-6
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019 [published correction appears in Lancet. 2020;396(10262):1562]. Lancet. 2020;396(10258):1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9
GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the global burden of Disease Study 2019. Lancet. 2020;396(10258):1160–203. https://doi.org/10.1016/s0140-6736(20)30977-6
doi: 10.1016/s0140-6736(20)30977-6
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1223–49. https://doi.org/10.1016/s0140-6736(20)30752-2
doi: 10.1016/s0140-6736(20)30752-2
Wang F, Mubarik S, Zhang Y, Shi W, Yu C. Risk assessment of dietary factors in global pattern of ischemic heart disease mortality and disability-adjusted life years over 30 years. Front Nutr. 2023;10:1151445. https://doi.org/10.3389/fnut.2023.1151445 . Published 2023 Jun 14.
doi: 10.3389/fnut.2023.1151445
pubmed: 37388629
pmcid: 10300343
Yang Y, Land FKC. A methodological comparison of age-period-cohort models: the intrinsic estimator and conventional generalized linear models. Sociol Methodol. 2004;34:75–110.
doi: 10.1111/j.0081-1750.2004.00148.x
Luo L. Assessing validity and application scope of the intrinsic estimator approach to the age-period-cohort problem. Demography. 2013;50(6):1945–67. https://doi.org/10.1007/s13524-013-0243-z
doi: 10.1007/s13524-013-0243-z
pubmed: 24072610
Sung H, Nisotel L, Sedeta E, Islami F, Jemal A. Racial and ethnic disparities in survival among people with second primary cancer in the US. JAMA Netw Open. 2023;6(8):e2327429. https://doi.org/10.1001/jamanetworkopen.2023.27429
doi: 10.1001/jamanetworkopen.2023.27429
pubmed: 37540510
pmcid: 10403787
Singh GK, Azuine RE, Siahpush M. Global inequalities in cervical cancer incidence and mortality are linked to deprivation, low socioeconomic status, and human development. Int J MCH AIDS. 2012;1(1):17–30. https://doi.org/10.21106/ijma.12
doi: 10.21106/ijma.12
pubmed: 27621956
pmcid: 4948158
Jiang D, Niu Z, Tan X, He H, Ren L, Shen J, et al. The mortalities of female-specific cancers in China and other countries with distinct socioeconomic statuses: a longitudinal study. J Adv Res. 2023;49:127–39. https://doi.org/10.1016/j.jare.2022.09.002
doi: 10.1016/j.jare.2022.09.002
pubmed: 36130684
Gondos A, Brenner H, Wabinga H, Parkin DM. Cancer survival in Kampala, Uganda. Br J Cancer. 2005;92(9):1808–12. https://doi.org/10.1038/sj.bjc.6602540
doi: 10.1038/sj.bjc.6602540
pubmed: 15827554
pmcid: 2362045
Dickson KS, Boateng ENK, Acquah E, Ayebeng C, Addo IY. Screening for cervical cancer among women in five countries in sub-saharan Africa: analysis of the role played by distance to health facility and socio-demographic factors. BMC Health Serv Res. 2023;23(1):61. Published 2023 Jan 20. https://doi.org/10.1186/s12913-023-09055-w
Simms KT, Yuill S, Killen J, Smith MA, Kulasingam S, de Kok I, et al. Historical and projected hysterectomy rates in the USA: implications for future observed cervical cancer rates and evaluating prevention interventions. Gynecol Oncol. 2020;158(3):710–8. https://doi.org/10.1016/j.ygyno.2020.05.030
doi: 10.1016/j.ygyno.2020.05.030
pubmed: 32723676
pmcid: 8723888
Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P, et al. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer. 2021;148(2):277–84. https://doi.org/10.1002/ijc.33189
doi: 10.1002/ijc.33189
pubmed: 32638362
Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389(10071):847–60. https://doi.org/10.1016/s0140-6736(16)31392-7
doi: 10.1016/s0140-6736(16)31392-7
pubmed: 27814965
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203. https://doi.org/10.1016/s2214-109x(19)30482-6
doi: 10.1016/s2214-109x(19)30482-6
pubmed: 31812369
He WQ, Li C. Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends. Gynecol Oncol. 2021;163(3):583–92. https://doi.org/10.1016/j.ygyno.2021.10.075
doi: 10.1016/j.ygyno.2021.10.075
pubmed: 34688503
Malagón T, Kulasingam S, Mayrand MH, et al., et al. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study [published correction appears in Lancet Oncol. 2019;20(1):e10]. Lancet Oncol. 2018;19(12):1569–78. https://doi.org/10.1016/S1470-2045(18)30536-9
doi: 10.1016/S1470-2045(18)30536-9
pubmed: 30392810
Azangou-Khyavy M, Ghasemi E, Rezaei N, et al. Global, regional, and national quality of care index of cervical and ovarian cancer: a systematic analysis for the global burden of disease study 1990–2019. BMC Womens Health. 2024;24(1):69. https://doi.org/10.1186/s12905-024-02884-9
doi: 10.1186/s12905-024-02884-9
pubmed: 38273304
pmcid: 10809627
Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health. 2023;11(2):e197–206. https://doi.org/10.1016/s2214-109x(22)00501-0
doi: 10.1016/s2214-109x(22)00501-0
pubmed: 36528031
Honarvar Z, Zarisfi Z, Salari Sedigh S, Masoumi Shahrbabak M. Comparison of conventional and liquid-based Pap smear methods in the diagnosis of precancerous cervical lesions. J Obstet Gynaecol. 2022;42(6):2320–4. https://doi.org/10.1080/01443615.2022.2049721
doi: 10.1080/01443615.2022.2049721
pubmed: 35579303
Reis NVS, Andrade BB, Guerra MR, Teixeira MTB, Malta DC, Passos VMA. The global burden of disease study estimates of Brazil’s cervical cancer burden. Ann Glob Health. 2020;86(1):56. https://doi.org/10.5334/aogh.2756
doi: 10.5334/aogh.2756
pubmed: 32566484
pmcid: 7292105
Lebanova H, Stoev S, Naseva E, Getova V, Wang W, Sabale U, et al. Economic burden of cervical cancer in Bulgaria. Int J Environ Res Public Health. 2023;20(3). https://doi.org/10.3390/ijerph20032746
Ong SK, Abe SK, Thilagaratnam S, Haruyama R, Pathak R, Jayasekara H, et al. Towards elimination of cervical cancer - human papillomavirus (HPV) vaccination and cervical cancer screening in Asian National Cancer Centers Alliance (ANCCA) member countries. Lancet Reg Health West Pac. 2023;39:100860 https://doi.org/10.1016/j.lanwpc.2023.100860
doi: 10.1016/j.lanwpc.2023.100860
Wang Z, Guo E, Yang B, Xiao R, Lu F, You L, et al. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: cervical, ovarian and uterine cancer. Gynecol Oncol. 2021;163(2):358–63. https://doi.org/10.1016/j.ygyno.2021.08.029
doi: 10.1016/j.ygyno.2021.08.029
pubmed: 34507827
Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:106399. https://doi.org/10.1016/j.ypmed.2020.106399
doi: 10.1016/j.ypmed.2020.106399
pubmed: 33388322
Duan R, Zhang H, Yu J, Deng S, Yang H, Zheng YT, et al. Temporal trends and projections of gynecological cancers in China, 2007–2030. BMC Womens Health. 2023;23(1):346. https://doi.org/10.1186/s12905-023-02384-2
doi: 10.1186/s12905-023-02384-2
pubmed: 37391767
pmcid: 10311708
Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90. https://doi.org/10.1097/cm9.0000000000002108
doi: 10.1097/cm9.0000000000002108
pubmed: 35143424
La Vecchia C, Rota M, Malvezzi M, Negri E. Potential for improvement in cancer management: reducing mortality in the European Union. Oncologist. 2015;20(5):495–8. https://doi.org/10.1634/theoncologist.2015-0011
doi: 10.1634/theoncologist.2015-0011
pubmed: 25888268
pmcid: 4425394
Zhang D, Zhao Y, Wang T, Xi Y, Li N, Huang H. Diabetes mellitus and long-term mortality of ovarian cancer patients. A systematic review and meta-analysis of 12 cohort studies. Diabetes Metab Res Rev. 2017;33(4). https://doi.org/10.1002/dmrr.2868
Vrachnis N, Iavazzo C, Iliodromiti Z, Sifakis S, Alexandrou A, Siristatidis C, et al. Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives. Arch Gynecol Obstet. 2016;293(2):239–46. https://doi.org/10.1007/s00404-015-3858-z
doi: 10.1007/s00404-015-3858-z
pubmed: 26338721
Dai H, Alsalhe TA, Chalghaf N, Riccò M, Bragazzi NL, Wu J. The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017: an analysis of the global burden of disease study. PLoS Med. 2020;17(7):e1003198. https://doi.org/10.1371/journal.pmed.1003198 . Published 2020 Jul 28.
doi: 10.1371/journal.pmed.1003198
pubmed: 32722671
pmcid: 7386577
Li X, Han F, Liu N, et al. Changing trends of the diseases burden attributable to high BMI in Asia from 1990 to 2019: results from the global burden of disease study 2019. BMJ Open. 2023;13(10):e075437. https://doi.org/10.1136/bmjopen-2023-075437 . Published 2023 Oct 21.
doi: 10.1136/bmjopen-2023-075437
pubmed: 37865409
pmcid: 10603495
Yang L, Yuan Y, Zhu R, Zhang X. Time trend of global uterine cancer burden: an age-period-cohort analysis from 1990 to 2019 and predictions in a 25-year period. BMC Womens Health. 2023;23(1):384. https://doi.org/10.1186/s12905-023-02535-5
doi: 10.1186/s12905-023-02535-5
pubmed: 37480027
pmcid: 10362563
Li W, Xu Y, Zeng X, Tan J, Wang Y, Wu H, et al. Etiological relationship between lipid metabolism and endometrial carcinoma. Lipids Health Dis. 2023;22(1):116. https://doi.org/10.1186/s12944-023-01868-2
doi: 10.1186/s12944-023-01868-2
pubmed: 37537560
pmcid: 10401764
Smrz SA, Calo C, Fisher JL, Salani R. An ecological evaluation of the increasing incidence of endometrial cancer and the obesity epidemic. Am J Obstet Gynecol. 2021;224(5):506e. https://doi.org/10.1016/j.ajog.2020.10.042
doi: 10.1016/j.ajog.2020.10.042
Dunneram Y, Greenwood DC, Cade JE. Diet, menopause and the risk of ovarian, endometrial and breast cancer. Proc Nutr Soc. 2019;78(3):438–48. https://doi.org/10.1017/s0029665118002884
doi: 10.1017/s0029665118002884
pubmed: 30706844
Beavis AL, Cheema S, Holschneider CH, Duffy EL, Amneus MW. Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk. Gynecol Oncol Rep. 2015;13:71–5. https://doi.org/10.1016/j.gore.2015.07.002
doi: 10.1016/j.gore.2015.07.002
pubmed: 26425728
pmcid: 4563798
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38. https://doi.org/10.1056/NEJMoa021423
doi: 10.1056/NEJMoa021423
pubmed: 12711737